Recombinant multi-species RUNX2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine RUNX2 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene is a member of the RUNX family of transcription factors and encodes a nuclear protein with an Runt DNA-binding domain. This protein is essential for osteoblastic differentiation and skeletal morphogenesis and acts as a scaffold for nucleic acids and regulatory factors involved in skeletal gene expression. The protein can bind DNA both as a monomer or, with more affinity, as a subunit of a heterodimeric complex. Two regions of potential trinucleotide repeat expansions are present in the N-terminal region of the encoded protein, and these and other mutations in this gene have been associated with the bone development disorder cleidocranial dysplasia (CCD). Transcript variants that encode different protein isoforms result from the use of alternate promoters as well as alternate splicing. [provided by RefSeq, Jul 2016]
The Alternative Names of target: AML3,Acute myeloid leukemia 3 protein,CBF-alpha-1,CBFA1,CCD,CCD1,CLCD,Cbf,Cbfa-1,Cbfa1,Core-binding factor subunit alpha-1 (CBF-alpha-1),LS3,OSF-2,OSF2,Oncogene AML-3,Osf2,Osteoblast-specific transcription factor 2 (OSF-2),PEA2aA,PEBP2-alpha A),PEBP2aA,Pebp2a1,Pebpa2a,Polyomavirus enhancer-binding protein 2 alpha A subunit (PEA2-alpha A,RUNX2,Runt-related transcription factor 2,Runx2,SL3-3 enhancer factor 1 alpha A subunit,SL3/AKV core-binding factor alpha A subunit
Go
to RUNX2 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T02259-Ag-1/ GM-Tg-hg-T02259-Ag-2 | Human RUNX2 protein | Human |
| GM-Tg-rg-T02259-Ag-1/ GM-Tg-rg-T02259-Ag-2 | Rat RUNX2 protein | Rat |
| GM-Tg-mg-T02259-Ag-1/ GM-Tg-mg-T02259-Ag-2 | Mouse RUNX2 protein | Mouse |
| GM-Tg-cynog-T02259-Ag-1/ GM-Tg-cynog-T02259-Ag-2 | Cynomolgus/Rhesus macaque RUNX2 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T02259-Ag-1/ GM-Tg-felg-T02259-Ag-2 | Feline RUNX2 protein | Feline |
| GM-Tg-cang-T02259-Ag-1/ GM-Tg-cang-T02259-Ag-2 | Canine RUNX2 protein | Canine |
| GM-Tg-bovg-T02259-Ag-1/ GM-Tg-bovg-T02259-Ag-2 | Bovine RUNX2 protein | Bovine |
| GM-Tg-equg-T02259-Ag-1/ GM-Tg-equg-T02259-Ag-2 | Equine RUNX2 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-T02259-Ag-1/ GM-Tg-hg-T02259-Ag-2;
GM-Tg-rg-T02259-Ag-1/ GM-Tg-rg-T02259-Ag-2;
GM-Tg-mg-T02259-Ag-1/ GM-Tg-mg-T02259-Ag-2; GM-Tg-cynog-T02259-Ag-1/ GM-Tg-cynog-T02259-Ag-2; GM-Tg-felg-T02259-Ag-1/ GM-Tg-felg-T02259-Ag-2; GM-Tg-cang-T02259-Ag-1/ GM-Tg-cang-T02259-Ag-2; GM-Tg-bovg-T02259-Ag-1/ GM-Tg-bovg-T02259-Ag-2; GM-Tg-equg-T02259-Ag-1/ GM-Tg-equg-T02259-Ag-2 |
| Products Name | RUNX2 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | RUNX2 |
| Protein Sub-location | Introcelluar Protein |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine RUNX2 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.